JP2003535133A5 - - Google Patents

Download PDF

Info

Publication number
JP2003535133A5
JP2003535133A5 JP2002501436A JP2002501436A JP2003535133A5 JP 2003535133 A5 JP2003535133 A5 JP 2003535133A5 JP 2002501436 A JP2002501436 A JP 2002501436A JP 2002501436 A JP2002501436 A JP 2002501436A JP 2003535133 A5 JP2003535133 A5 JP 2003535133A5
Authority
JP
Japan
Prior art keywords
depression
pharmaceutical composition
weight
famotidine
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002501436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535133A (ja
Filing date
Publication date
Priority claimed from HU0002154A external-priority patent/HUP0002154A3/hu
Application filed filed Critical
Publication of JP2003535133A publication Critical patent/JP2003535133A/ja
Publication of JP2003535133A5 publication Critical patent/JP2003535133A5/ja
Withdrawn legal-status Critical Current

Links

JP2002501436A 2000-06-06 2001-06-06 うつ病またはうつ様症状の治療のための医薬組成物 Withdrawn JP2003535133A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0002154 2000-06-06
HU0002154A HUP0002154A3 (en) 2000-06-06 2000-06-06 Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
PCT/HU2001/000065 WO2001093863A2 (en) 2000-06-06 2001-06-06 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression

Publications (2)

Publication Number Publication Date
JP2003535133A JP2003535133A (ja) 2003-11-25
JP2003535133A5 true JP2003535133A5 (enExample) 2010-11-18

Family

ID=89978380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002501436A Withdrawn JP2003535133A (ja) 2000-06-06 2001-06-06 うつ病またはうつ様症状の治療のための医薬組成物

Country Status (10)

Country Link
US (1) US20040010021A1 (enExample)
EP (1) EP1289520B1 (enExample)
JP (1) JP2003535133A (enExample)
AT (1) ATE302000T1 (enExample)
AU (1) AU2001266242A1 (enExample)
DE (1) DE60112750T2 (enExample)
DK (1) DK1289520T3 (enExample)
ES (1) ES2247137T3 (enExample)
HU (1) HUP0002154A3 (enExample)
WO (1) WO2001093863A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
US20150329540A1 (en) 2012-12-28 2015-11-19 Shin Nippon Biomedical Laboratories, Ltd. Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
EP3018125B1 (en) 2013-07-03 2020-08-05 Shin Nippon Biomedical Laboratories, Ltd. Novel compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
IL311338A (en) * 2024-03-07 2025-10-01 Ariel Scient Innovations Ltd Using hyaluronic acid to treat mental disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
AU7322394A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-sucralfate-antiflatulent combinations
AU7218294A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations

Similar Documents

Publication Publication Date Title
Hui et al. Nasal CPAP reduces systemic blood pressure in patients with obstructive sleep apnoea and mild sleepiness
JP2002532432A5 (enExample)
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
JP2008509224A5 (enExample)
JP2020520963A5 (enExample)
JP2004537500A5 (enExample)
Schuchmann et al. Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature
JP2003535133A5 (enExample)
CN115350236A (zh) 用于管理癌症和治疗癌症并存病的方法
CN1406609A (zh) 一种可用于治疗中风和胸痹的中药胶囊剂及其制法
CN102488768B (zh) 治疗痛风的中药药物
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
JP5764655B2 (ja) 薬物常用癖を治療するための薬剤組成物
CN100500180C (zh) 具有祛痰、镇咳、平喘、解热作用的药物组合物
CN107080786A (zh) 抗抑郁症药物组合物及其制备方法和应用以及包含其的药物或药物组合物
WO2004081195A3 (en) Use of secretin and secretin analogs to treat affective disorders
JP2004262775A5 (enExample)
CN1111051C (zh) 一种治疗咳、喘病的药物
Tyagi et al. Ketamine—a review of published cases
JP2022011233A (ja) 下肢疲労改善剤
Ingenito et al. S69 Retrospective analysis of physiological response patterns to tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR or heterozygous for f508del-CFTR and a residual function mutation
CN1175862C (zh) 一种治疗痔疮的药物
CN1045534C (zh) 去疣组合物
Hasan et al. Amyotrophic lateral sclerosis presenting with orthopnea in a patient with COPD and obstructive sleep apnea
JPH10175860A5 (enExample)